ESC 365 - Pharmacological selectivity of SGLT2 inhibitors and cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis

ESC Professional Premium Access

Pharmacological selectivity of SGLT2 inhibitors and cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis

Session: SGLT2 inhibitors in clinical practice

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor A. Sayour (Budapest, HU)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Alex Ali Sayour

Semmelweis University Heart and Vascular Center, Budapest (Hungary)

0 follower

6 more presentations in this session

Absolute treatment effects of novel oral antidiabetic drugs on cardiovascular mortality and hospitalization for heart failure: a meta-analysis of digitalized individual patient outcomes

Speaker: Mr G. Wolff (Ibbenbüren, DE)

The gender gap in prescription pattern of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes

Speaker: Mr A. Hammer (Vienna, AT)

Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease

Speaker: Doctor D. Chipayo Gonzales (Caceres, ES)

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study

Speaker: Mr O. Chou (Hong Kong, HK)

Characterization of the SGLT2 interaction network and its regulation by SGLT2 inhibitors: a bioinformatic analysis

Speaker: Miss A. Nowak (Warsaw, PL)

Access the full session

SGLT2 inhibitors in clinical practice

Speakers: Doctor A. Sayour, Mr G. Wolff, Mr A. Hammer, Doctor D. Chipayo Gonzales, Mr O. Chou...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources